Professional-grade financial intelligence

20M+ securities. Real-time data. Institutional insights.

Subscribe for $2

Trusted by professionals at Goldman Sachs, BlackRock, and JPMorgan

Overview
Profile
Morphic Holding Stock

Morphic Holding Stock MORF

MORF
US61775R1059
A2PLX9

Price

56.99
Today +/-
+0
Today %
+0 %

Morphic Holding stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Morphic Holding stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Morphic Holding stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Morphic Holding stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Morphic Holding's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Morphic Holding Stock Price History

DateMorphic Holding Price
8/14/202456.99 undefined
8/13/202456.97 undefined

Morphic Holding Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Morphic Holding, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Morphic Holding from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Morphic Holding’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Morphic Holding. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Morphic Holding’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Morphic Holding’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Morphic Holding’s growth potential.

Morphic Holding Revenue, EBIT and net profit per share

DateMorphic Holding RevenueMorphic Holding EBITMorphic Holding Net Income
2029e381.13 M undefined-128.86 M undefined-49.08 M undefined
2028e156.53 M undefined-226.39 M undefined-147.96 M undefined
2027e1.22 M undefined-312.28 M undefined-215.07 M undefined
2026e408,000 undefined-272.2 M undefined-191.55 M undefined
2025e291,424.19 undefined-248.56 M undefined-183.66 M undefined
2024e255,000 undefined-228.7 M undefined-172.67 M undefined
2023521,000 undefined-178.69 M undefined-152.1 M undefined
202270.81 M undefined-63.4 M undefined-59.04 M undefined
202119.79 M undefined-95.81 M undefined-95.54 M undefined
202044.95 M undefined-47.18 M undefined-45 M undefined
201916.98 M undefined-46.99 M undefined-43.33 M undefined
20183.36 M undefined-24.63 M undefined-23.83 M undefined
20170 undefined-16.93 M undefined-16.92 M undefined

Morphic Holding Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
031644197000001156381
--433.33175.00-56.82268.42-----15,500.00144.23
-------------
0000000000000
-16-23-43-45-95-59-152-172-183-191-215-147-49
-43.7586.964.65111.11-37.89157.6313.166.404.3712.57-31.63-66.67
29.629.630.1130.5935.838.1142.39000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Morphic Holding Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Morphic Holding is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (k)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (k)
SHORT-TERM REC. (M)
LONG-T. LIAB. (k)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
2017201820192020202120222023
             
20.8185.9237228408.1348.2704.35
003.57.32.30.50
0000000
0000000
0.51.23.14.27.913.512.58
21.3187.1243.6239.5418.3362.2716.93
1.71.83.42.67.45.64.9
0000000
0000000
0000000
0000000
300300400300600800686
22.13.82.986.45.59
23.3189.2247.4242.4426.3368.6722.51
             
49.7139.800000.01
000.240.290.580.651.14
-30.4-54.2-97.5-142.5-238.1-297.1-449.19
0000000
0000-0.5-3.32.29
2087.2140.9145.2336.6349.1697.02
0.91.75.23.84.83.57.7
1.33.26.610.212.813.217.08
029.923.525.420.60.50
0000000
300000000
2.534.835.339.438.217.224.78
300000000
0000000
0.467.171.257.751.32.30.72
0.767.171.257.751.32.30.72
3.2101.9106.597.189.519.525.49
23.2189.1247.4242.3426.1368.6722.51
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Morphic Holding provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Morphic Holding's financial health and stability.

Assets

Morphic Holding's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Morphic Holding must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Morphic Holding after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Morphic Holding's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (k)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-16-23-43-45-95-59-152
0001,0001,0001,0001,000
0000000
098-1-13-11-728
02522435971
0000000
0000000
-1576-41-45-83-100-112
00-20-10-1
00-1358-113-56-341
00-1338-112-56-340
0000000
0000000
20909342406368
2089933826645453
00033253984
0000000
3165-84069-1120
-16.3775.68-43.81-46.53-84.48-101.35-113.55
0000000

Morphic Holding stock margins

The Morphic Holding margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Morphic Holding. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Morphic Holding.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Morphic Holding's sales revenue. A higher gross margin percentage indicates that the Morphic Holding retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Morphic Holding's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Morphic Holding's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Morphic Holding's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Morphic Holding. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Morphic Holding's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Morphic Holding Margin History

Morphic Holding Gross marginMorphic Holding Profit marginMorphic Holding EBIT marginMorphic Holding Profit margin
2029e0 %-33.81 %-12.88 %
2028e0 %-144.63 %-94.53 %
2027e0 %-25,513.06 %-17,570.9 %
2026e0 %-66,715.96 %-46,947.59 %
2025e0 %-85,291.25 %-63,019.87 %
2024e0 %-89,687.11 %-67,711.86 %
20230 %-34,296.74 %-29,192.9 %
20220 %-89.54 %-83.38 %
20210 %-484.13 %-482.77 %
20200 %-104.96 %-100.11 %
20190 %-276.74 %-255.18 %
20180 %-733.04 %-709.23 %
20170 %0 %0 %

Morphic Holding Stock Sales Revenue, EBIT, Earnings per Share

The Morphic Holding earnings per share therefore indicates how much revenue Morphic Holding has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Morphic Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Morphic Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Morphic Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Morphic Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Morphic Holding Revenue, EBIT and net profit per share

DateMorphic Holding Sales per ShareMorphic Holding EBIT per shareMorphic Holding Earnings per Share
2029e8.99 undefined0 undefined-1.16 undefined
2028e3.69 undefined0 undefined-3.49 undefined
2027e0.03 undefined0 undefined-5.07 undefined
2026e0.01 undefined0 undefined-4.52 undefined
2025e0.01 undefined0 undefined-4.33 undefined
2024e0.01 undefined0 undefined-4.07 undefined
20230.01 undefined-4.22 undefined-3.59 undefined
20221.86 undefined-1.66 undefined-1.55 undefined
20210.55 undefined-2.68 undefined-2.67 undefined
20201.47 undefined-1.54 undefined-1.47 undefined
20190.56 undefined-1.56 undefined-1.44 undefined
20180.11 undefined-0.83 undefined-0.81 undefined
20170 undefined-0.57 undefined-0.57 undefined

Morphic Holding business model

Morphic Holding Inc. is a pharmaceutical company that focuses on developing therapies for serious diseases. The company was founded in 2015 and is based in Waltham, Massachusetts. The company's business model is centered around developing drugs based on "Morphic Molecules" that are specifically designed to interact with certain target proteins in the body. These molecules aim to improve the treatment of diseases such as autoimmune diseases and fibrosis. Morphic Holding Inc. collaborates closely with leading scientists in the field of structural biology to develop new therapy options for patients. The company has formed partnerships with Biogen, Janssen Biotech, and AbbVie to collaboratively develop new medications. In addition to partnering with other leading companies in the healthcare industry, Morphic Holding Inc. also maintains its own research department focused on the discovery and development of new compounds. The company has applied for and been granted several patents for its "Morphic Molecules," further strengthening its ability to develop innovative therapies for serious diseases. One of Morphic Holding Inc.'s current products is a drug for the treatment of cystic fibrosis that is still in the development phase. The company is working to advance its research and development in this area to continue offering innovative therapies for patients. Morphic Holding Inc. is also involved in biotechnological development and offers services to assist other companies in developing new compounds. These services include the identification and validation of target proteins, the design and synthesis of molecules, and the optimization of drug properties. In conclusion, Morphic Holding Inc. is an emerging force in the pharmaceutical development field. The company has a unique approach to drug development and has already established partnerships with other companies and leading research institutions to develop new therapy options for patients. With its commitment to innovation and research, Morphic Holding Inc. is likely to continue making significant advancements in the field of medicine in the future. Morphic Holding is one of the most popular companies on Eulerpool.com.

Morphic Holding SWOT Analysis

Strengths

Morphic Holding Inc possesses several strengths that contribute to its success in the market. One of its key strengths is its strong and experienced management team, which has a deep understanding of the industry. This enables the company to make informed decisions and navigate challenges effectively.

Furthermore, Morphic Holding Inc has a diverse portfolio of innovative products and solutions, which gives it a competitive edge in the market. Its focus on research and development ensures that it stays ahead of its competitors by continuously improving and expanding its offerings.

Weaknesses

While Morphic Holding Inc has numerous strengths, it also faces certain weaknesses that need to be addressed. One of its weaknesses is its limited market presence compared to some of its larger competitors. This makes it more challenging for the company to penetrate new markets and gain significant market share.

Additionally, Morphic Holding Inc heavily relies on a few key customers for a significant portion of its revenue. This dependency poses a risk, as any loss of these customers could have a negative impact on the company's financial performance.

Opportunities

There are several opportunities available for Morphic Holding Inc to capitalize on and fuel its growth. The increasing demand for its products and solutions, driven by market trends and technological advancements, presents a significant opportunity for the company to expand its customer base and increase its market share.

Furthermore, the company has the potential to enter new geographic markets where its products are not yet widely available. By strategically targeting these untapped markets, Morphic Holding Inc can tap into new revenue streams and diversify its customer base.

Threats

Despite its strengths and opportunities, Morphic Holding Inc also faces certain threats that could impact its performance. One of the major threats is intense competition from established players in the industry. This competition can lead to pricing pressures and reduced market share if the company is unable to differentiate itself effectively.

Moreover, regulatory changes and compliance requirements pose a potential threat to Morphic Holding Inc. Changes in regulations or non-compliance with existing ones can create operational challenges and legal liabilities, affecting the company's reputation and financial stability.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Morphic Holding Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Morphic Holding historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Morphic Holding shares outstanding

The number of shares was Morphic Holding in 2024 — This indicates how many shares 42.391 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Morphic Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Morphic Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Morphic Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Morphic Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Morphic Holding.

Morphic Holding latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.99 -1.15  (-15.96 %)2024 Q2
3/31/2024-0.94 -0.91  (3.67 %)2024 Q1
12/31/2023-0.87 -0.96  (-10.84 %)2023 Q4
9/30/2023-0.97 -0.73  (25.01 %)2023 Q3
6/30/2023-0.89 -0.92  (-3.41 %)2023 Q2
3/31/2023-0.83 -0.9  (-8.59 %)2023 Q1
12/31/2022-0.89 -0.64  (28.15 %)2022 Q4
9/30/2022-0.85 -0.78  (7.87 %)2022 Q3
6/30/2022-0.87 0.68  (178.2 %)2022 Q2
3/31/2022-0.83 -0.85  (-2.88 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Morphic Holding stock

Eulerpool World ESG Rating (EESG©)

47/ 100

🌱 Environment

49

👫 Social

61

🏛️ Governance

30

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Morphic Holding shareholders

%
Name
Stocks
Change
Date
7.13869 % Springer Timothy A3,026,133-4,608,0528/16/2024
4.69597 % Polaris Venture Partners1,990,65104/1/2024
1.44955 % Tipirneni (Praveen P)614,474-42,4608/16/2024
0.34512 % Nomura Asset Management Co., Ltd.146,300146,30011/30/2023
0.30422 % Medical Strategy GmbH128,962-313,05112/31/2023
0.07804 % Wellington Management Singapore Pte. Ltd.33,0811,3306/30/2024
0.07490 % Wellington Management Japan Pte Ltd31,751-13,4476/30/2023
0.05229 % DeVaul (William David)22,16707/8/2024
0.03656 % T. Rowe Price Japan, Inc.15,500-9,2998/31/2024
0.03259 % Neuberger Berman Investment Advisors LLC13,81313,8137/31/2024
1
2
3
4
5
...
10

Morphic Holding Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Schrodinger Stock
Schrodinger
SupplierCustomer-0,360,700,490,710,860,03
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer-0,50-0,43-0,45-0,59-0,420,55
Hitgen A Stock
Hitgen A
SupplierCustomer-0,540,550,650,790,87-0,47
AbbVie Stock
AbbVie
SupplierCustomer-0,610,700,07-0,67-0,850,22
1

Most common questions regarding Morphic Holding

What values and corporate philosophy does Morphic Holding represent?

Morphic Holding Inc represents a set of core values and corporate philosophies that drive their operations. With a focus on innovation, they are committed to pushing boundaries and delivering groundbreaking solutions in the biopharmaceutical industry. As a company, Morphic Holding Inc values integrity, transparency, and ethical practices, ensuring they uphold the highest standards in all their endeavors. By fostering a collaborative environment, they encourage teamwork, diverse perspectives, and a shared passion for making a positive impact on patients' lives. Morphic Holding Inc's dedication to excellence and patient-centric approach defines their identity and drives their pursuit of pioneering therapeutic advancements.

In which countries and regions is Morphic Holding primarily present?

Morphic Holding Inc is primarily present in the United States.

What significant milestones has the company Morphic Holding achieved?

Morphic Holding Inc has achieved significant milestones since its establishment. The company successfully completed its initial public offering (IPO) and listed on the Nasdaq stock exchange under the ticker symbol MORF. Moreover, Morphic Holding Inc has made notable advancements in its drug discovery research and development programs, particularly in the field of integrin-targeted therapies. This has allowed the company to progress multiple drug candidates into various stages of clinical trials, highlighting its dedication to addressing unmet medical needs. Morphic Holding Inc continues to strive for excellence in the pharmaceutical industry, constantly pushing boundaries to bring innovative treatments to patients worldwide.

What is the history and background of the company Morphic Holding?

Morphic Holding Inc is a reputable company specializing in the field of biotechnology. Founded in 2014, Morphic focuses on developing integrin-targeted therapeutics for chronic inflammatory and autoimmune diseases. The company boasts a talented team of scientists and researchers dedicated to advancing new treatment options. Morphic has collaborated with several renowned institutions and pharmaceutical companies to develop novel drugs targeting specific integrins, thus making significant strides in the field of biopharmaceuticals. With their rich history and strong track record, Morphic Holding Inc continues to make promising advancements in the biotechnology industry, showcasing their commitment to improving global healthcare.

Who are the main competitors of Morphic Holding in the market?

The main competitors of Morphic Holding Inc in the market include pharmaceutical companies such as Biogen Inc, Amgen Inc, and Regeneron Pharmaceuticals Inc. These companies operate in the biotechnology industry and focus on developing innovative therapies and drugs for various conditions. By being aware of the competitive landscape, investors and individuals interested in Morphic Holding Inc can gain insights into the market dynamics and potential challenges the company may face.

In which industries is Morphic Holding primarily active?

Morphic Holding Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Morphic Holding?

The business model of Morphic Holding Inc is focused on discovering and developing oral small molecule integrin therapeutics. These therapeutics aim to treat chronic diseases by selectively targeting integrins, which are proteins involved in cell adhesion and signaling. Morphic Holding Inc's proprietary Morphic Integrin Therapeutics (MIT) platform enables the design of integrin-targeting drug candidates with improved selectivity, efficacy, and safety profiles. By leveraging their expertise in drug discovery and integrin biology, Morphic Holding Inc strives to advance potential treatments for conditions such as autoimmune diseases, fibrosis, and cancers.

What is the P/E ratio of Morphic Holding 2025?

The Morphic Holding P/E ratio is -13.15.

What is the P/S ratio of Morphic Holding 2025?

The Morphic Holding P/S ratio is 8,289.77.

What is the Quality Investing of Morphic Holding?

The Quality Investing for Morphic Holding is 2/10.

What is the revenue of Morphic Holding 2025?

The expected Morphic Holding revenue is 291,424.19 USD.

How high is the profit of Morphic Holding 2025?

The expected Morphic Holding profit is -183.66 M USD.

What is the business model of Morphic Holding

Morphic Holding Inc is a US-based biotechnology company focused on the discovery and development of drugs based on the science of integrin pharmacology. The company was founded in 2015 and is listed on the Nasdaq stock exchange under the symbol "MORF". This article will describe the business model of Morphic Holding Inc. Integrin pharmacology is a novel therapeutic strategy that specifically targets integrins to modulate specific cell/tissue interactions. Integrins are protein molecules on the surface of cells that are responsible for cell adhesion, cell migration, and signal transduction, making them important targets for drug development. Morphic Holding Inc has a strong portfolio of proprietary molecules that modulate integrins to treat diseases such as inflammatory bowel disease, fibrosis, cancer, pain, and autoimmune diseases. The company also has strategic partnerships with leading pharmaceutical companies such as AbbVie, Janssen, and Schrödinger to further intensify their research. Morphic's business model involves developing innovative drugs based on integrin pharmacology and licensing them to pharmaceutical companies. The company pursues a dual strategy by independently advancing its own pipeline while also demonstrating the value of its technology platform through collaborations. Morphic's product portfolio includes several drugs in development targeting fibrosis, inflammatory bowel disease, cancer, and autoimmune diseases. The lead product candidate, MORF-057, is a selective integrin α4β7 antagonist developed for the treatment of inflammatory bowel disease and is currently in Phase 2 clinical trials. Furthermore, the company recently completed the acquisition of Morphic Therapeutic Europe Limited, a company focused on researching and developing integrin-mediated tumor metastasis blockade. This acquisition expands Morphic's portfolio with innovative preclinical drug candidates for the treatment of cancer based on integrins. In summary, Morphic Holding Inc has an innovative business model based on integrin pharmacology. The company develops drugs targeting a variety of diseases by specifically modulating integrins. Their products are currently in development and have the potential to achieve significant therapeutic advancements. Through strategic partnerships and acquisitions, the company is further expanding its position in the biotechnology sector.

What is the Morphic Holding dividend?

Morphic Holding pays a dividend of 0 USD distributed over payouts per year.

How often does Morphic Holding pay dividends?

The dividend cannot currently be calculated for Morphic Holding or the company does not pay out a dividend.

What is the Morphic Holding ISIN?

The ISIN of Morphic Holding is US61775R1059.

What is the Morphic Holding WKN?

The WKN of Morphic Holding is A2PLX9.

What is the Morphic Holding ticker?

The ticker of Morphic Holding is MORF.

How much dividend does Morphic Holding pay?

Over the past 12 months, Morphic Holding paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Morphic Holding is expected to pay a dividend of 0 USD.

What is the dividend yield of Morphic Holding?

The current dividend yield of Morphic Holding is .

When does Morphic Holding pay dividends?

Morphic Holding pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Morphic Holding?

Morphic Holding paid dividends every year for the past 0 years.

What is the dividend of Morphic Holding?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Morphic Holding located?

Morphic Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Morphic Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Morphic Holding from 7/31/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2025.

When did Morphic Holding pay the last dividend?

The last dividend was paid out on 7/31/2025.

What was the dividend of Morphic Holding in the year 2024?

In the year 2024, Morphic Holding distributed 0 USD as dividends.

In which currency does Morphic Holding pay out the dividend?

The dividends of Morphic Holding are distributed in USD.

All fundamentals about Morphic Holding

Our stock analysis for Morphic Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Morphic Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.